Clinical Trial Update: A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety, pharmacokinetics, and pharmacodynamics of ISIS 416858 administered subcutaneously to patients with end-stage renal disease on he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• ISIS 416858

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: End-stage Renal Disease (ESRD) | Phase 2 | Status: COMPLETED